Even though I'm not one to talk with regards this and another biospec, diversification rules should never be ignored.
Some might say that a $16 figure will first largely depend on successful Phase 3 trial results exCorp, whilst I tend to believe our big hurdle will be the FDA themselves.
There has in the past been much controversy with this mob and the Dendreon story was certainly no stranger to this issue.
From my understanding the FDA at first did not approve Provenge before, at Dendreon's request the US Government intervened with an enquiry into their own department.
If anyone can offer further information i'd be very interested because if I recall I believe this doing was due to FDA panel members having a conflict of interest with investments in another company?
Even though I'm not one to talk with regards this and another...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.015(4.23%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.8¢ | 33.5¢ | $1.374M | 3.957M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 95461 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 48512 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |